Financials Wuhan Keqian Biology Co.,Ltd

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
18.29 ^CNY	-1.93%		+0.66%	-10.26%

Apr. 29	Wuhan Keqian Biology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Wuhan Keqian Biology Co.,Ltd's Equity Buyback Plan announced on February 22, 2024.	CI

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	19,344	12,805	10,443	9,501	8,526	-	-
Enterprise Value (EV) ¹	19,344	12,805	10,443	9,501	8,526	8,526	8,526
P/E ratio	35.9 x	22.4 x	25.5 x	22.6 x	16.9 x	13.2 x	12.4 x
Yield	-	0.69%	0.85%	2.11%	1.49%	1.84%	2.05%
Capitalization / Revenue	22.9 x	11.6 x	10.4 x	8.91 x	6.77 x	5.49 x	5.01 x
EV / Revenue	22.9 x	11.6 x	10.4 x	8.91 x	6.77 x	5.49 x	5.01 x
EV / EBITDA	34.5 x	17.7 x	18.5 x	16.6 x	12.7 x	10.1 x	9.67 x
EV / FCF	-	-	32.5 x	21.9 x	21 x	20.8 x	12.7 x
FCF Yield	-	-	3.07%	4.57%	4.76%	4.8%	7.91%
Price to Book	7.14 x	4.06 x	2.99 x	2.46 x	2.02 x	1.78 x	1.63 x
Nbr of stocks (in thousands)	465,000	465,133	466,208	466,168	466,168	-	-
Reference price ²	41.60	27.53	22.40	20.38	18.29	18.29	18.29
Announcement Date	2/25/21	2/25/22	2/27/23	2/26/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	507.5	843.2	1,103	1,001	1,066	1,260	1,552	1,701
EBITDA ¹	-	561.3	723.6	563.7	572.6	674	843	881.5
EBIT ¹	-	524.3	661	466.7	483	581.8	742.5	793.8
Operating Margin	-	62.18%	59.93%	46.61%	45.32%	46.17%	47.83%	46.66%
Earnings before Tax (EBT) ¹	-	519.7	660	466.6	481.8	580.7	741.3	792.8
Net income ¹	-	447.8	570.7	409.5	418.4	504	645.3	688.4
Net margin	-	53.11%	51.74%	40.9%	39.26%	40%	41.57%	40.47%
EPS ²	0.6700	1.160	1.230	0.8800	0.9000	1.081	1.385	1.475
Free Cash Flow ¹	-	-	-	320.9	433.7	406	409	674
FCF margin	-	-	-	32.05%	40.69%	32.22%	26.35%	39.62%
FCF Conversion (EBITDA)	-	-	-	56.94%	75.74%	60.24%	48.52%	76.46%
FCF Conversion (Net income)	-	-	-	78.37%	103.66%	80.55%	63.38%	97.91%
Dividend per Share ²	-	-	0.1900	0.1900	0.4300	0.2733	0.3367	0.3750
Announcement Date	9/2/20	2/25/21	2/25/22	2/27/23	2/26/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-	321	434	406	409	674
ROE (net income / shareholders' equity)	-	27.5%	19.6%	12.4%	11.5%	12.1%	13.6%	13.3%
ROA (Net income/ Total Assets)	-	-	16.7%	10.1%	9.17%	9.53%	9.77%	9.01%
Assets ¹	-	-	3,418	4,058	4,565	5,292	6,605	7,638
Book Value Per Share ²	-	5.820	6.780	7.500	8.280	9.040	10.30	11.30
Cash Flow per Share ²	-	0.8600	1.140	0.9100	1.150	1.100	1.260	1.540
Capex ¹	-	-	374	103	104	72.1	85.3	107
Capex / Sales	-	-	33.95%	10.26%	9.79%	5.72%	5.49%	6.26%
Announcement Date	9/2/20	2/25/21	2/25/22	2/27/23	2/26/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

18.29 CNY

Average target price

26.04 CNY

Spread / Average Target

+42.39%

	1st Jan change	Capi.
WUHAN KEQIAN BIOLOGY CO.,LTD	-10.26%	1.18B
ZOETIS INC.	-14.35%	77.13B
ELANCO ANIMAL HEALTH INCORPORATED	+14.09%	8.4B
VIRBAC	-0.70%	3.22B
VIMIAN GROUP AB	+14.70%	1.64B
JINYU BIO-TECHNOLOGY CO., LTD.	-10.12%	1.5B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-22.60%	1.3B
VETOQUINOL SA	-4.20%	1.25B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	+5.06%	1.1B
PULIKE BIOLOGICAL ENGINEERING, INC.	-12.05%	950M